- Home
- TSHA vs ECX Comparison
TSHA vs ECX Comparison
Compare TSHA & ECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- ECX
- Stock Information
- Founded
- TSHA 2019
- ECX 2017
- Country
- TSHA United States
- ECX China
- Employees
- TSHA N/A
- ECX N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- ECX EDP Services
- Sector
- TSHA Health Care
- ECX Technology
- Exchange
- TSHA Nasdaq
- ECX Nasdaq
- Market Cap
- TSHA 728.4M
- ECX 589.5M
- IPO Year
- TSHA 2020
- ECX N/A
- Fundamental
- Price
- TSHA $2.65
- ECX $1.60
- Analyst Decision
- TSHA Strong Buy
- ECX Strong Buy
- Analyst Count
- TSHA 6
- ECX 1
- Target Price
- TSHA $8.17
- ECX $3.20
- AVG Volume (30 Days)
- TSHA 2.6M
- ECX 6.6M
- Earning Date
- TSHA 08-11-2025
- ECX 08-07-2025
- Dividend Yield
- TSHA N/A
- ECX N/A
- EPS Growth
- TSHA N/A
- ECX N/A
- EPS
- TSHA N/A
- ECX N/A
- Revenue
- TSHA $7,224,000.00
- ECX $805,604,079.00
- Revenue This Year
- TSHA N/A
- ECX $26.72
- Revenue Next Year
- TSHA N/A
- ECX $30.72
- P/E Ratio
- TSHA N/A
- ECX N/A
- Revenue Growth
- TSHA N/A
- ECX 19.98
- 52 Week Low
- TSHA $1.05
- ECX $0.76
- 52 Week High
- TSHA $3.31
- ECX $3.25
- Technical
- Relative Strength Index (RSI)
- TSHA 56.06
- ECX 44.71
- Support Level
- TSHA $2.34
- ECX $1.20
- Resistance Level
- TSHA $2.81
- ECX $2.40
- Average True Range (ATR)
- TSHA 0.16
- ECX 0.24
- MACD
- TSHA 0.01
- ECX -0.07
- Stochastic Oscillator
- TSHA 67.37
- ECX 33.47
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.